Cargando…
Incidence and predictors of acquired resistance to second-line antituberculosis drugs during the course of multi-drug resistant tuberculosis treatment: protocol for a systematic review and meta-analysis
INTRODUCTION: To date, acquired resistance to second-line antituberculosis drugs (SLDs) during multi-drug resistant tuberculosis (MDR-TB) treatment is becoming a public health concern. Different studies have assessed the incidence of acquired resistance to SLDs. However, the findings are inconsisten...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083796/ https://www.ncbi.nlm.nih.gov/pubmed/37019479 http://dx.doi.org/10.1136/bmjopen-2022-070143 |
_version_ | 1785021599487885312 |
---|---|
author | Alemu, Ayinalem Bitew, Zebenay Workneh Diriba, Getu Gashu, Emebet Seid, Getachew Eshetu, Kirubel Kebede, Abebaw Gumi, Balako |
author_facet | Alemu, Ayinalem Bitew, Zebenay Workneh Diriba, Getu Gashu, Emebet Seid, Getachew Eshetu, Kirubel Kebede, Abebaw Gumi, Balako |
author_sort | Alemu, Ayinalem |
collection | PubMed |
description | INTRODUCTION: To date, acquired resistance to second-line antituberculosis drugs (SLDs) during multi-drug resistant tuberculosis (MDR-TB) treatment is becoming a public health concern. Different studies have assessed the incidence of acquired resistance to SLDs. However, the findings are inconsistent and there is limited global evidence. Thus, we are going to assess the incidence and predictors of acquired resistance to SLDs during MDR-TB treatment. METHODS AND ANALYSIS: We designed this protocol following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist. Electronic databases and grey literature sources will be searched systematically for articles published up to 25 March 2023. Studies reporting the incidence and predictors of acquired resistance to SLDs in MDR-TB patients will be explored. The studies will be managed using Endnote X8 citation manager and a stepwise approach will be followed to select studies. Data will be summarised using Microsoft Excel 2016 spreadsheet. A Newcastle-Ottawa Scale quality assessment and cochrane risk-of-bias tools will be used to assess the study’s quality. The authors will independently search databases, select studies, assess the study’s quality and extract data. Data will be analysed using STATA V.17 software. We will estimate the pooled incidence of acquired resistance with 95% CI. In addition, the pooled effect measures (OR, HR, risk ratio) with their 95% CI will be estimated. Heterogeneity will be assessed using the I(2) statistics. Publication bias will be assessed using funnel plot and Egger’s test. A subgroup analysis will be conducted for the primary outcome (acquired resistance) per each study characteristics such as WHO regional category, country’s TB/MDR-TB burden, data collection period and per the specific second-line anti-TB drug. ETHICS AND DISSEMINATION: Since this study will be based on data extraction from published studies, ethical approval is not mandatory. The study will be published in peer-reviewed scientific journals and the findings will be presented at different scientific conferences. PROSPERO REGISTRATION NUMBER: CRD42022371014. |
format | Online Article Text |
id | pubmed-10083796 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-100837962023-04-11 Incidence and predictors of acquired resistance to second-line antituberculosis drugs during the course of multi-drug resistant tuberculosis treatment: protocol for a systematic review and meta-analysis Alemu, Ayinalem Bitew, Zebenay Workneh Diriba, Getu Gashu, Emebet Seid, Getachew Eshetu, Kirubel Kebede, Abebaw Gumi, Balako BMJ Open Infectious Diseases INTRODUCTION: To date, acquired resistance to second-line antituberculosis drugs (SLDs) during multi-drug resistant tuberculosis (MDR-TB) treatment is becoming a public health concern. Different studies have assessed the incidence of acquired resistance to SLDs. However, the findings are inconsistent and there is limited global evidence. Thus, we are going to assess the incidence and predictors of acquired resistance to SLDs during MDR-TB treatment. METHODS AND ANALYSIS: We designed this protocol following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist. Electronic databases and grey literature sources will be searched systematically for articles published up to 25 March 2023. Studies reporting the incidence and predictors of acquired resistance to SLDs in MDR-TB patients will be explored. The studies will be managed using Endnote X8 citation manager and a stepwise approach will be followed to select studies. Data will be summarised using Microsoft Excel 2016 spreadsheet. A Newcastle-Ottawa Scale quality assessment and cochrane risk-of-bias tools will be used to assess the study’s quality. The authors will independently search databases, select studies, assess the study’s quality and extract data. Data will be analysed using STATA V.17 software. We will estimate the pooled incidence of acquired resistance with 95% CI. In addition, the pooled effect measures (OR, HR, risk ratio) with their 95% CI will be estimated. Heterogeneity will be assessed using the I(2) statistics. Publication bias will be assessed using funnel plot and Egger’s test. A subgroup analysis will be conducted for the primary outcome (acquired resistance) per each study characteristics such as WHO regional category, country’s TB/MDR-TB burden, data collection period and per the specific second-line anti-TB drug. ETHICS AND DISSEMINATION: Since this study will be based on data extraction from published studies, ethical approval is not mandatory. The study will be published in peer-reviewed scientific journals and the findings will be presented at different scientific conferences. PROSPERO REGISTRATION NUMBER: CRD42022371014. BMJ Publishing Group 2023-04-05 /pmc/articles/PMC10083796/ /pubmed/37019479 http://dx.doi.org/10.1136/bmjopen-2022-070143 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Infectious Diseases Alemu, Ayinalem Bitew, Zebenay Workneh Diriba, Getu Gashu, Emebet Seid, Getachew Eshetu, Kirubel Kebede, Abebaw Gumi, Balako Incidence and predictors of acquired resistance to second-line antituberculosis drugs during the course of multi-drug resistant tuberculosis treatment: protocol for a systematic review and meta-analysis |
title | Incidence and predictors of acquired resistance to second-line antituberculosis drugs during the course of multi-drug resistant tuberculosis treatment: protocol for a systematic review and meta-analysis |
title_full | Incidence and predictors of acquired resistance to second-line antituberculosis drugs during the course of multi-drug resistant tuberculosis treatment: protocol for a systematic review and meta-analysis |
title_fullStr | Incidence and predictors of acquired resistance to second-line antituberculosis drugs during the course of multi-drug resistant tuberculosis treatment: protocol for a systematic review and meta-analysis |
title_full_unstemmed | Incidence and predictors of acquired resistance to second-line antituberculosis drugs during the course of multi-drug resistant tuberculosis treatment: protocol for a systematic review and meta-analysis |
title_short | Incidence and predictors of acquired resistance to second-line antituberculosis drugs during the course of multi-drug resistant tuberculosis treatment: protocol for a systematic review and meta-analysis |
title_sort | incidence and predictors of acquired resistance to second-line antituberculosis drugs during the course of multi-drug resistant tuberculosis treatment: protocol for a systematic review and meta-analysis |
topic | Infectious Diseases |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083796/ https://www.ncbi.nlm.nih.gov/pubmed/37019479 http://dx.doi.org/10.1136/bmjopen-2022-070143 |
work_keys_str_mv | AT alemuayinalem incidenceandpredictorsofacquiredresistancetosecondlineantituberculosisdrugsduringthecourseofmultidrugresistanttuberculosistreatmentprotocolforasystematicreviewandmetaanalysis AT bitewzebenayworkneh incidenceandpredictorsofacquiredresistancetosecondlineantituberculosisdrugsduringthecourseofmultidrugresistanttuberculosistreatmentprotocolforasystematicreviewandmetaanalysis AT diribagetu incidenceandpredictorsofacquiredresistancetosecondlineantituberculosisdrugsduringthecourseofmultidrugresistanttuberculosistreatmentprotocolforasystematicreviewandmetaanalysis AT gashuemebet incidenceandpredictorsofacquiredresistancetosecondlineantituberculosisdrugsduringthecourseofmultidrugresistanttuberculosistreatmentprotocolforasystematicreviewandmetaanalysis AT seidgetachew incidenceandpredictorsofacquiredresistancetosecondlineantituberculosisdrugsduringthecourseofmultidrugresistanttuberculosistreatmentprotocolforasystematicreviewandmetaanalysis AT eshetukirubel incidenceandpredictorsofacquiredresistancetosecondlineantituberculosisdrugsduringthecourseofmultidrugresistanttuberculosistreatmentprotocolforasystematicreviewandmetaanalysis AT kebedeabebaw incidenceandpredictorsofacquiredresistancetosecondlineantituberculosisdrugsduringthecourseofmultidrugresistanttuberculosistreatmentprotocolforasystematicreviewandmetaanalysis AT gumibalako incidenceandpredictorsofacquiredresistancetosecondlineantituberculosisdrugsduringthecourseofmultidrugresistanttuberculosistreatmentprotocolforasystematicreviewandmetaanalysis |